This article reviews the commonly used drugs targeting VEGF/VEGFR and Ang/Tie and the clinical studies targeting both targets simultaneously, as well as several novel dual-target anti-tumor angiogenesis drugs. The gene discussed is KDR; the disease is neoplasm.